tbuckley/cabot-search huggingface dataset:
Altered cardiac responsiveness and regulation in the normal cardiac output type of borderlind hlpertension.
Authors: S Julius, O S Randall, M D Esler, T Kashima, C Ellis, J Bennett
Journal: Circulation Research (1975)

Of 145 patients with borderline hypertension, 30% had increased resting cardiac index (QI), whereas the remainder had normal values. The specific aim of this study was to investigate cardiac regulation in patients who had normal resting QI. Eighty-five control subjects were used for comparison. At rest, patients with normal QI showed evidence of decreased parasympathetic inhibition; the QI after injection of atropine increased less than in control subjects. After complete cardiac autonomic blockade with propranolol and atropine, QI and stroke volume were significantly lower in patients than in control subjects. The mechanism of this low QI was further analyzed. Central blood volume, which strongly correlates with stroke volume, was used as an estimate of the cardiac venous filling. After blockade, stroke volume was decreased in patients, but central blood volume was normal. Patients also showed a decreased heart rate and QI response to infusion of isoproterenol. It is therefore postulated that two components may be responsible for the low QI in the "denervated" heart: patients exhibit a decreased responsiveness to sympathetic stimulation, and they may also be less responsive to venous filling. Behind the facade of cardiac normality in these borderline hypertensive patients with normal cardiac output, there is evidence of altered autonomic control of the heart (decreased vagal inhibition) and of changed cardiac response to sympathetic stimulation and possibly to venous filling.
Inherited cardiovascular diseases: identification of silent/subclinical forms by screening target groups
Authors: Aris Anastasakis, Artemisia Theopistou, Angelos Rigopoulos, Evangelia Karvouni, Nikos Protonotarios, Dimitris Markou, Elias Sevdalis, Nikos Mamalis, Christodoulos Stefanadis, Pavlos Toutouzas
Journal: Journal of the American College of Cardiology (2002)
Chronic Myeloid Leukemia Stem Cells
Authors: Edward Kavalerchik, Daniel Goff, Catriona H.M. Jamieson
Journal: Journal of Clinical Oncology (2008)

Although rare, chronic myeloid leukemia (CML) represents an important paradigm for understanding the molecular events leading to malignant transformation of primitive hematopoietic progenitors. CML was the first cancer to be associated with a defined genetic abnormality, BCR-ABL, that is necessary and sufficient for initiating chronic phase disease as well as the first cancer to be treated with molecular targeted therapy. Malignant progenitors or leukemia stem cells (LSCs) evolve as a result of both epigenetic and genetic events that alter hematopoietic progenitor differentiation, proliferation, survival, and self-renewal. LSCs are rare and divide less frequently, and thus, represent a reservoir for relapse and resistance to a molecularly targeted single agent. On subverting developmental processes normally responsible for maintaining robust life-long hematopoiesis, the LSCs are able to evade the majority of current cancer treatments that target rapidly dividing cells. Enthusiasm for the enormous success of tyrosine kinase inhibitors at controlling the chronic phase disease is tempered somewhat by the persistence of the LSC pool in the majority of the patients. Combined therapies targeting aberrant properties of LSC may obviate therapeutic resistance and relapse in advanced phase and therapeutically recalcitrant CML.
Topical sodium cromoglycate and atopic eczema
Authors: T.J. David
Journal: British Journal of Dermatology (1985)

Journal Article Topical sodium cromoglycate and atopic eczema Get access T.J. David T.J. David Department of Child Health, Booth Hall Children's Hospital, Manchester M9 2AA, U.K. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 113, Issue 6, 1 December 1985, Page 797, https://doi.org/10.1111/j.1365-2133.1985.tb02415.x Published: 01 December 1985
Therapeutic Bronchoscopy in Broncholithiasis
Authors: ERIC J. OLSON, JAMES P. UTZ, UDAYA B. S. PRAKASH
Journal: American Journal of Respiratory and Critical Care Medicine (1999)

Bronchoscopy is considered the most important diagnostic test for broncholithiasis. However, its role in the treatment of broncholithiasis in a large group of patients has not been studied. To evaluate the therapeutic role of bronchoscopy, we retrospectively reviewed the clinical data of patients with broncholithiasis who also underwent bronchoscopy at Mayo Clinic. Bronchoscopy revealed 127 broncholiths (free or partly eroded calcified material in the airway lumen) in 95 patients (49 men and 46 women) evaluated between 1954 and 1994. Bronchoscopic removal of 71 (56%) broncholiths was attempted in 48 patients (50.5%) during 61 bronchoscopy sessions. Forty-eight of the broncholiths selected for removal were partly eroding into the tracheobronchial lumen and 23 were free. Forty-eight percent (23 of 48) of the partly eroding broncholiths were successfully removed bronchoscopically, with a greater percentage removed with the rigid bronchoscope (67%) than with the flexible bronchoscope (30%). All free broncholiths were completely extracted regardless of the type of bronchoscope used. Complications occurred in only two patients (4% of the bronchoscopic broncholithectomy group), both with partially eroded broncholiths, and consisted of hemorrhage in one patient requiring thoracotomy and acute dyspnea in another patient, caused by a loose broncholith lodged in the trachea. We conclude that flexible and/or rigid bronchoscopic extraction of partly eroded or free broncholiths in the tracheobronchial tree can be considered safe and effective.
Retinoid metabolism and mode of action.
Authors: L M De Luca, W Sasak, S Adamo, P V Bhat, I Akalovsky, C S Silverman-Jones, N Maestri
Journal: Environmental Health Perspectives (1980)

Vitamin A and its derivaties (retinoids) are necessary for the maintenance of normal phenotypic expression. An attempt at understanding the biochemical role of vitamin A had led to the demonstration of a new pathway for retinol. In this pathway, vitamin A is phosphorylated to retinylphosphate (RP), which is then glycosylated to retinylphosphatemannose (MRP). These two derivatives have been found in a variety of tissues in vivo and in vitro and appear to be ubiquitous components of cellular membranes. The suggestion has been made that MRP may mediate specific cellular interactions by functioning as a lipid intermediate in the biosynthesis of specific glycoconjugates. A study on spontaneously-transformed mouse fibroblasts (Balb/c 3T12-3 cells) has shown that retinoids are active in increasing the adhesive properties of these cells as measured in an EDTA-mediated detachment assay. Various retinoids were tested for their activity in the adhesion test, and this activity was found to correlate well with their biological activity in maintaining the expression of normal epithelial differentiation in other systems. Retinoic acid, 5,6-epoxyretinol, and 5,6-epoxyretinoic acid were the most active compounds. Retinoids without biological activity in other systems were also inactive in inducihg adhesive properties of 3T12-3 cells. Among these were the synthetic derivatives of retinol, anhydroretinol, and 4,5-monoeneperhydroretinol, and the phenyl derivative of retinoic acid. Beta-Ionone, abscisic acid, and juvenile hormone, which are devoid of vitamin A activity in other systems, were also inactive in this system. Retinoid-induced changes in cell surface proteins were investigated but no difference in 125I-fibronectin (MW 220,000) was detectable between retinoid-treated and untreated cells. However, these cells synthesized retinylphosphatemannose and the incorporation of 2-3H-mannose into a specific glycoprotein (gp 180) was found to be enhanced specifically by retinoid treatment. Investigations of the involvement of gp 180 in adhesion are in progress.
1066 ACCELERATED FIBROSIS PROGRESSION IN HIV/HCV-COINFECTED PATIENTS UNDER EFFECTIVE ANTIRETROVIRAL THERAPY
Authors: J. Macías, M.A. von Wichmann, A. Rivero, F. Téllez, D. Merino, M. Márquez, A. Vergara, M. Delgado, J.A. Mira, J.A. Pineda
Journal: Journal of Hepatology (2010)
Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study
Authors: Peter A. Campochiaro, David M. Brown, Carl C. Awh, S. Young Lee, Sarah Gray, Namrata Saroj, Wendy Yee Murahashi, Roman G. Rubio
Journal: Ophthalmology (2011)
Recovery of a Newly Recognized Enterovirus from Patients with Aseptic Meningitis
Authors: Edwin H. Lennette, Nathalie J. Schmidt, Robert L. Magoffin, Anna Wiener
Journal: New England Journal of Medicine (1962)

ATTEMPTS to isolate a virus in this laboratory over the past six years on stool specimens from patients with symptoms of Central-nervous-system disease have yielded 16 strains immunologically identical to an ECHO-virus candidate strain (Caldwell). This report describes illnesses in persons from whom the strains were recovered as well as serologic responses of the patients and family contacts.Materials and MethodsIsolation AttemptsThe virus strains were all isolated from stool suspensions in monkey-kidney cell cultures by a procedure described elsewhere.1 Neutralizing-Antibody AssaysPaired serum specimens from patients whose stools yielded virus and from their family contacts were assayed for . . .
Mesenteric artery thrombosis: A case report of combined protein S and protein C deficiency
Authors: Kristen A. Atkins, James L. Zehnder
Journal: American Journal of Hematology (1998)

Individuals with more than one defect in natural coagulant/anticoagulant systems have been postulated to be at an increased risk for thrombotic events. We report a case of combined protein S and C deficiency in a young woman, which resulted in fatal arterial mesenteric thrombosis. The role of coagulation defects in arterial thrombosis is discussed. Am. J. Hematol. 58:246–247, 1998. © 1998 Wiley-Liss, Inc.
Military's Counterdrug Policy Restructured
Authors: Phil Gunby
Journal: JAMA (1994)

DEFENSE DEPARTMENT officials are making changes in the military's 5-year war on drugs. For one thing, there probably will be fewer mentions of its being a war. Brian E. Sheridan, deputy assistant secretary of defense for drug enforcement policy and support, says the term<i>drug war</i>(since the Department of Defense was drafted into the counterdrug effort in 1989) has implied misleadingly that battle lines are clearly drawn and a day of victory can be predicted. His first year in this assignment, he says, has taught him the importance of recognizing that illicit drug use is a deepseated social problem to be addressed by many agencies in a variety of ways and over the long term. <h3>Supporting Role Suggested</h3> In that regard, the Clinton administration has announced a 1994 National Drug Control Strategy, indicating that numerous agencies should cooperate to attack the drug problem simultaneously in various ways. Sheridan says
Low dose desensitisation does not reduce the toxicity of sulphasalazine in rheumatoid arthritis.
Authors: I B McInnes, D Porter, E A Murphy, E A Thomson, R Madhok, J A Hunter, T Pullar, H A Capell
Journal: Annals of the Rheumatic Diseases (1996)

To examine the proposal that pretreatment low dose desensitisation may reduce the incidence of toxicity of sulphasalazine in the treatment of rheumatoid arthritis (RA).A double blind, placebo controlled trial was performed with 422 patients satisfying the American College of Rheumatology criteria for RA who required sulphasalazine treatment because of increased disease activity. Patients received either sulphasalazine desensitisation, or placebo, for three weeks before commencement of sulphasalazine treatment. The frequency and nature of adverse effects and changes in clinical and laboratory parameters of disease activity were measured after three and six months.Improvement in the efficacy of sulphalasazine (measured by clinical and laboratory parameters) was significant and similar in magnitude in both groups. There was no significant difference between actively and placebo desensitised patients as regards the incidence or profile of adverse effects (toxicity).Pretreatment low dose desensitisation is unhelpful in reducing the toxicity associated with sulphasalazine treatment of RA.
EFFECTIVENESS OF CORONARY ARTERY CALCIUM SCORING FOR LONG-TERM RISK STRATIFICATION IN PATIENTS WITH AND WITHOUT A FAMILY HISTORY OF CORONARY HEART DISEASE
Authors: Joseph T. Knapper, Michael Blaha, Daniel Berman, Arshed Quyyumi, Matthew Budoff, Tracy Callister, James Min, Leslee Shaw
Journal: Journal of the American College of Cardiology (2014)
Der Vereinsamte als Patient
Authors: E.A.D.E. Carp
Journal: Psychotherapy and Psychosomatics (1966)

Research Articles| February 11 2010 Der Vereinsamte als Patient Subject Area: Psychiatry and Psychology E.A.D.E. Carp E.A.D.E. Carp Oegstgeest Search for other works by this author on: This Site PubMed Google Scholar Psychother Psychosom (1966) 14 (3): 186–198. https://doi.org/10.1159/000285824 Article history Published Online: February 11 2010 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation E.A.D.E. Carp; Der Vereinsamte als Patient. Psychother Psychosom 1 March 1966; 14 (3): 186–198. https://doi.org/10.1159/000285824 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsPsychotherapy and Psychosomatics Search Advanced Search This content is only available via PDF. 1966Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Article PDF first page preview Close Modal You do not currently have access to this content.
Hexokinase “New Hyde Park”: A low activity erythrocyte isozyme in a chinese kindred
Authors: Donald E. Paglia, Ashok Shende, Philip Lanzkowsky, William N. Valentine
Journal: American Journal of Hematology (1981)

Abstract Chronic hemolytic anemia in a 7‐year‐old Chinese boy was found to be associated with decreased activity of erythrocyte hexokinase (approximately 20% of appropriate control values). Alterations in kinetics, stability, pH optimum, or electrophoretic patterns could not be demonstrated with proband hexokinase, but subtle differences between maternal and paternal hexokinase characteristics suggested that two separate mutant isozymes were involved and that the proband was heterozygous for each. Comparisons with previously reported cases of hexokinase deficiency demonstrate the broad genetic heterogeneity that characterizes this disorder.
Abstract 5626: FKBP51 is a crucial modulator of melanoma plasticity and promising molecular target for preventing melanoma metastasis
Authors: Maria Fiammetta Romano, Simona Romano, Stefania Staibano, Adelaide Greco, Arturo Brunetti, Gennaro Ilardi, Massimo Mascolo, Rita Bisogni, Bruno Alfano
Journal: Cancer Research (2012)

Abstract FKBP51, a protein with a relevant role in developmental stages in mammals and other organisms, is highly expressed in melanoma and correlates with tumor aggressiveness and resistance to therapy. We found that FKBP51 positively regulates melanoma cancer stem cell (CSC) phenotype at the transcriptional level. We also found that melanoma CSCs are endowed with epithelial to mesenchimal transition (EMT) traits. The immunochemistry study of 10 primitive cutaneous and 20 brain melanoma metastases showed that melanocytic cells capable of extravasation and subverting the architecture of metastatic tissue display intense FKBP51 nuclear signal and cytoplasmic positivity for the CSC marker nestin. These findings support the conclusion that the genetic programs of cancer stemness and invasiveness overlap in melanoma, and that FKBP51 plays a pivotal role in sustaining such a program. To confirm the role of FKBP51 in melanoma invasion, we utilized an experimental metastasis model. Animal studies were performed in accordance with NIH recommendations and the approval of the local institutional animal research committee. Injecting SAN melanoma cells into the tail vein of IL2γ-NOD-SCID mice produced prominent multifocal lesions in lungs and liver. We systemically administered two separate doses of FKBP51 siRNA to mice after the injection of melanoma cells. Organ colonization was evaluated both in live animals and post mortem. Qualitative PET/CT image analysis demonstrated low FDG uptake limited to small areas in lungs and liver. By contrast, untreated mice had diffuse metastatic liver and lung lesions and high FDG uptake in the same organs. Quantitative analysis performed on PET/CT images revealed that mean standardized uptake values (SUV) in treated mice were significantly lower than in untreated mice, both for lungs and liver. High Frequency Ultrasound examination revealed few or no liver metastases in treated mice versus untreated mice. Post-mortem organ examination showed a dramatic difference between the morphologically preserved organs dissected from treated mice, and severely compromised organs from untreated mice. The histological examination confirmed these findings. Most interestingly, invading cells co-expressed FKBP51 and nestin. Our study suggests a prominent role for FKBP51 in the pathogenesis of metastatic melanoma; we envision that targeting this protein for melanoma metastasis prevention may produce a successful outcome. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5626. doi:1538-7445.AM2012-5626
Abstract 2181: Tumor suppressor role of Notch3 in medullary thyroid carcinoma
Authors: Renata Jaskula-Sztul, Jacob Eide, Muthusamy Kunnimalaiyaan, Herbert Chen
Journal: Cancer Research (2011)

Abstract Introduction: NOTCH3 is a transmembrane receptor that appears to be absent in the neuroendocrine (NE) tumors. We have previously demonstrated that transient expression of the active portion of NOTCH3 (NICD3) alters the NE phenotype and inhibits the proliferation of carcinoid tumor cells in vitro. However, the long term effect of activation this pathway is not clearly understood in Medullary Thyroid Carcinoma (MTC). To elucidate the role of Notch3 in NE, we established a doxycycline inducible NOTCH3 intracellular domain in MTC TT cells. The aim of this study was to assess the long term effect of NOTCH3 and determine the mechanism of inhibition of TT cells growth. Methods: Doxycycline inducible TT-NOTCH3 cells were created by stable transfection of Tet-On vector followed by transfection of pRevTRE-NOTCH3 plasmid. Functional analysis of NICD3 was done by measuring the degree of luciferase activity by CBF binding assay. Quantification of HES and HEY gene expression (Notch signaling mediators) was done by real time RT-PCR. Effect of Notch3 on NE markers -chromogranin A (CgA) and achaete-scute complex-like1 (ASCL1) – was assessed by Western blot analysis. The influence of NOTCH3 overexpression on TT-NOTCH cell proliferation was measured by the methylthiazolyldiphenyl-tetrazolium bromide (MTT) rapid colorimetric assay. The mechanism of growth inhibition was determined for apoptosis markers by Western blot and flow cytometry analyses. Results: Treatment of TT-NOTCH3 cells with doxycycline led to an induction of NOTCH3 protein in a dose-dependent manner. Increase in the CBF1 binding activity showed that the NOTCH3 protein is functional and this is associated with changes in transcriptional level of HES and HEY families. More importantly, NOTCH3 activation led to a dose dependant reduction of NE markers ASCL1 and CgA. In addition, NOTCH3 activity is required to suppress MTC cell proliferation and the level of growth regression depends on the amount of NOTCH3 protein expressed. Finally, Western blot analysis and flow cytometry experiments indicated that the growth inhibition is due to apoptosis. Conclusions: We demonstrate, for the first time, that overexpression of NOTCH3 in MTC cells suppresses tumor cells growth by promoting apoptosis. Moreover, Notch3 pathway is functional as active NOTCH3 triggers the CBF-dependent transcriptional network. Finally, the activation of Notch3 in the in vitro model resulted in down-regulation of NE markers indicated that this pathway is conserved in MTC. Therefore, activation of Notch3 could be a therapeutic strategy to treat patients with MTC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2181. doi:10.1158/1538-7445.AM2011-2181